39 results about "Self-protein" patented technology

A method is disclosed for inducing cell-mediated immunity against cellular antigens. More specifically, the invention provides for a method for inducing cytotoxic T-lymphocyte immunity against weak antigens, notably self-proteins. The method entails that antigen presenting cells are induced to present at least one CTL epitope of the weak antigen and at the same time presenting at least one foreign T-helper lymphocyte epitope. In a preferred embodiment, the antigen is a cancer specific antigen, e.g. PSM, Her2, or FGF8b. The method can be exercised by using traditional polypeptide vaccination, but also by using live attenuated vaccines or nucleic acid vaccination. The invention furthermore provides immunogenic analogues of PSM, Her2 and FGF8b, as well as nucleic acid molecules encoding these analogues. Also vectors and transformed cells are disclosed. The invention also provides for a method for identification of immunogenic analogues of weak or non-immunogenic antigens.

The present invention relates to vaccines that are made in transgenic soybeans for use in humans, animals of agricultural importance, pets, and wildlife. These vaccines are used as vaccines against viral, bacterial, fungal, parasitic or prion related diseases, cancer antigens, toxins, and autologous or self proteins. The transgenic soybeans of the instant invention also can be used for inducing tolerance to allergens or tolerance to autoimmune antigens, wherein an individual shows hypersensitivity to said allergen or has developed autoimmunity to autologous or self proteins, respectively. The invention also relates to prophylatically treating individuals and/or populations prior to showing hypersensitivity to allergens. Other aspects of the invention include using the transgenic soybeans as an oral contraceptive, and the expression of protein adjuvants in transgenic soybeans.

A method and a product for cleaning and/or whitening of teeth. Natural human cysteine proteinases are employed for cleaning and whitening purposes and this activity can be blocked by natural cysteine protease inhibitors, which are released secondarily from the product at a later stage. The use of natural cysteine proteinases and their inhibitors provides the advantage that they are man's own proteins, and therefore the risk of allegorization is minimized. In addition, their enzyme kinetics are will known.

Mutations to the tumor suppressor protein p53 have been observed in 40-60% of all human cancers. These mutations are often associated with high nuclear and cytoplasmic concentrations of p53. Since many tumors exhibit highly elevated p53 levels, the protein is an attractive target for cancer immunotherapy. Unfortunately, p53 is an autoantigen that is likely to be tolerated as a self-protein by the immune system. The present invention is based on the discovery that this self-tolerance can be overcome by administration of recombinant modified vaccinia Ankara (MVA) containing a nucleic acid that encodes p53 (rMVAp53). The invention discloses a method of generating a p53-specific CTL-response to tumor cells expressing mutated p53 by administering a composition comprising rMVAp53. Administration of rMVAp53 decreases tumor development, tumor growth, and mortality in a variety of malignant cell types. These effects are enhanced by administration of CTLA-4 blocker and/or CpG oligodeoxynucleotide immunomodulators.

The invention discloses a cross-linking preparing method for heart valve prosthesis material, comprising a cross-linker, cross-linking steps and preserving treatment after cross-linking. The method is characterized in that the collected cardiac valve of a pig is timely and appropriately treated and cleaned, and then the cells are completely removed and cleaned, then the obtained cells are cross-linked by quercetin, thus improving the mechanical strength, further eliminating the antigenicity and enhancing the stability. The acellular bioprothesis cardiac valve of the pig adopts heart valve prosthesis prepared by the method has the advantages of non-toxic valve, high tensile strength, resistance to enzymic degradation and minimum release of the cross-linker and self-protein of valves. The cross-linking properties of the acellular bioprothesis cardiac valve made of cardiac valve material of the pig are beneficial to transplanting, proliferation, covering and long-term anti-calcification of interstitial cells of valves of the body of man and vascular endothelial cells after being transplanted into the human body.

The present invention is pneumococus polysaccharide protein coupling vaccine comprising covalently connected pneumococus capsule polysaccharide and recombinant pneumolysin without hemolytic activity modification and its preparation process. The vaccine has pneumolysin without hemolytic activity as protein carrier, no need of eliminating hemolysis toxicity of pneumolysin with formalin and ensured safety, and may be used for infant below 2 yeas old to prevent tympanitis. Owing to the pneumolysin as the self protein, the vaccine has no probable immune interference reaction and strengthened immune protecting effect. The vaccine has cross immunizing protection effect on various kinds of serum type pneumococus and raised immune memory response to pneumococus infection.

The invention discloses a method for preparing malt fragrance-flavour matter by utilizing self protein of wheat bran and sugar. The method disclosed by the invention is characterized by comprising the following steps: (1) baking wheat bran for improving aroma, and smashing for later use; (2) carrying out enzymolysis, namely adding the smashed wheat bran into an aqueous solution, adding alpha-amylase and maltase for carrying out enzymolysis, then adding flavoured proteinase for carrying out enzymolysis, then carrying out enzyme deactivation after enzymolysis is finished, centrifuging, removing impurities, and carrying out vacuum concentration, so that mixed enzymatic hydrolysate rich in reducing sugar, amino acid and small molecular peptides is obtained; and (3) carrying out Maillard reaction by taking the reducing sugar, amino acid and small molecular peptides in the mixed enzymatic hydrolysate, so that the mal fragrance-flavour matter product is obtained. The method disclosed by the invention is simple in steps and easy to operate, all the related raw materials are from the wheat bran, the amino acid and reducing sugar do not need to be added, the obtained flavour matter is close to the original malt fragrance to the utmost extend, and aroma is natural without other foreign flavour, thereby being applicable to popularization and application.

Type 1 diabetes (T1D) patients make antibodies to self-proteins that are potential biomarkers for early detection and risk prediction. We have identified seventeen antigens as biomarkers for early diagnosis and risk prediction of T1D, including the antigens MLH1, MTIF3, PPIL2, NUP50, TOX4, FIGN, C9orf142, ZNF280D, HES1, QRFPR, CTRC, SNX6, SYTL4, ELA2A, IGRP, PAX6, and HMGN3.

The invention relates to pharmaceutical vaccine compositions for treating or alleviating self-protein-mediated inflammatory pathologies, such as rheumatoid arthritis, Crohn's disease, enflammatory bowel disease, which vaccine compositions comprise a modified immunogenic self-protein and a surfactant capable of acting as a solubiliser. Compositions of modified human TNFalpha and cetylpyrimydium are provided.

The invention discloses a biological system for efficiently detecting sweetness strength of a to-be-detected matter by taking yeast cell as host on the basis of combining sweetness receptor protein T1R2/T1R3 with a detection gene path. The biological system comprises the sweetness receptor protein T1R2/T1R3 subjected to modification and codon optimization, a modified Gpa1 protein adaptive to T1R2/T1R3, a G protein coupling signal path for signal amplification without signal interference and an inducible detection gene path with fluorescent protein or enzyme as a reporter gene. After the to-be-detected matter is added into a culture environment and the sweet matter molecule is combined with the sweetness receptor, the host G protein coupling signal path is utilized to amplify the signal and activate a downstream detection path, the expression condition of the report gene is taken as signal output, and the sweetness strength of the sweet matter is represented by the signal output strength. The biological system disclosed by the invention has the advantages of simple culture condition, low cost, short period, wide detection scope, high repeatability, high stability and capability of realizing the efficient detection for the sweetness strength of different sweet matters.

The invention discloses a bacterial magnetic particle (BMP)-agglutinin complex and a preparation method and application thereof, belonging to the technical field of separation and purification. The preparation method comprises the following steps: performing surface modification and transformation on BMPs, and adding a cross-linking agent and agglutinin for coupling, thereby obtaining the BMP-agglutinin complex. The surfaces of the BMPs are modified, the influence of self-proteins of the BMPs on subsequent application is eliminated, more primary amino is provided for agglutinin coupling due to the addition of PE, the coupling efficiency is improved, and the dispersity of the BMPs is improved; the cross-linking agent (BS3) serves as a connecting arm, so that covalent coupling is realized between the BMPs and the agglutinin, and an agglutinin recognition sugar chain area is not damaged; and moreover, the concentration of a buffer solution is regulated, the preparation time is shortened, and the coupling efficiency is improved. The complex disclosed by the invention is used for enriching and separating specific glycoproteins, and compared with traditional affinity chromatography, the method disclosed by the invention has the advantages of fewer steps, short time and the like.

The present invention relates to hapten antibody preparing process, and is especially the process of first preparing complete antigen through coupling animal's autologous protein to hapten and subsequent preparing antibody through immunizing animal with the complete antigen. The antibody preparing process has no introduced foreign protein, body produced antibody targeting to the small molecular weight compound and small peptide hapten, and no antibody to autologous protein. Therefore, the prepared hapten antibody prepared with autologous protein as carrier protein has high valence and high specificity.

The invention discloses a high-protein culture medium for promoting volvariella volvacea protein synthesis. The high-protein culture medium is characterized by comprising the following components in parts by weight: 30-40 parts of corn straws, 20-30 parts of sawdust, 10-20 parts of astragalus smicus, 5-7 parts of attapulgite, 3-5 parts of nitrohumic acid, 0.4-0.5 part of lysine, 2-3 parts of ammonium hydrogen carbonate, 0.9-1.3 parts of basic zinc sulfate, 3-7 parts of chitosan fibers, 1-2 parts of a decomposed coal-sodium polyacrylate mixture and a proper amount of water. After enzymolysis, the raw materials are stirred and sintered in intense fire in an inert gas environment; after quick cooling, modified attapulgite loaded with proteins is formed; the corn straws with a deoiled naked fiber structure, the basic zinc sulfate and the other half of the attapulgite are mixed so as to prepare organic fiber zinc loaded on the attapulgite is prepared; absorption of volvariella volvacea to the zinc is promoted, so that synthesis of endoenzyme of volvariella volvacea is promoted, Dolores utilization of the proteins in a compost and synthesis of the own proteins are accelerated, and efficient growth of volvariella volvacea is realized.

The invention relates to a composition for the treatment of various cancers. The composition is a vaccine containing sequences of EDB, EDA, annexin A1, endosialin, C domain of tenascin C or magic roundabout (MR) or fragments thereof as single or in a combination coupled to one or several heterologous foreign carrier molecules. The vaccine will produce antibodies that are directed against self proteins which are preferentially expressed in and around tumor vessels. The vaccine is preferably administrated together with an adjuvant.

The present invention provides SELF protein having controlling effects on growth and differentiation of undifferentiated cells, wherein the protein contains a novel EGF-like repeat sequence, SELF gene encoding the same, a recombinant vector and a transformed cell containing the SELF gene, a method for treatment or prophylaxis with SELF protein or a recombinant expression vector containing SELF gene, SELF promoter, a recombinant vector and a transformed cell containing SELF promoter, and a screening method using the transformed cell containing SELF promoter.

The invention discloses a preparation method of adhesive for a paper tube, which belongs to the field of chemical industry. L-tartaric acid and acetyl chloride are used as raw materials, then thick phosphoric acid is added as a catalyst to perform the organic synthetic reaction under a heating condition, a reactant is used as a modifier to modify a prepared soybean-based adhesive substance and modify the prepared soybean-based adhesive, on the basis that the original four-level structure of the protein is broken through by virtue of alkaline treatment, the structure of the protein is further changed, the hydrophilic group and a hydrophobic group wrapped inside the globulin are exposed, so that a polypeptide is unfolded, the adhesion strength is improved, a large strong bond combination force can be generated between the protein molecules of the adhesive and between the protein molecule and paper tube cellulose in the curing process, and the pressure resistance is improved. By adoptingthe preparation method of the adhesive for the paper tube, the problems that the existing paper tube that the adhesion strength is low, the water resistance is poor and the pressure resisting strengthof the paper tube is greatly reduced along with the storage time can be solved.

This invention provides a method of treating or preventing a disease in an animal associated with one or more self-protein(s), -polypeptide(s), or -peptide(s) that is present or involved in a non-physiologic process in the animal comprising administering to the animal a self-vector comprising a polynucleotide encoding the self-protein(s), -polypeptide(s) or -peptide(s) associated with the disease.Administration of the self-vector comprising a polynucleotide encoding the self-protein(s), -polypeptide(s) or -peptide(s) modulates an immune response to the self-protein(s), -polypeptide(s) or -peptide(s) expressed from administration of the self-vector. The invention also provides a composition comprising a polynucleotide encoding one or more self-protein(s), -polypeptide(s), or -peptide(s) that is present non-physiologically in a treated animal useful in treating or preventing a disease associated with the self-protein(s), -polypeptide(s), or -peptide(s) present in and/or the target of anon-physiologic process in the animal.

The invention discloses a method for evaluating correlation between autoprotein and mesenchymal stem cell Th1 immunoregulation. The method comprises the following steps: cell culture, gene sequencing, differential gene screening, differential gene specifying, cell transfection, Th1 immunoregulation capability detection and Th1 immunoregulation capability evaluation. According to the method disclosed by the invention, the correlation between the autoprotein and the Th1 immunoregulation ability of the mesenchymal stem cells is further explored and evaluated according to the heterogeneity of different sources of MSCs in the aspect of Th1 immunoregulation inhibition, and a basis is provided for detecting the cell quality by utilizing the autoprotein expressed by the mesenchymal stem cells; when diseases are treated by immune regulation, a standard is provided for evaluating the immune regulation capability of the mesenchymal stem cells by detecting the expression quantity of the protein.

Proteomics is combined with mass spectrum identification to find that nitric oxide generated by staphylococcus aureus endogenously can cause nitrosation modification of protein of the staphylococcus aureus. Experiments prove that nitrosation modification of important transcriptional regulatory factors WalR and MgrA has the potential to become targets of vancomycin drug resistance treatment.